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Summary 
Due to its heterogeneity, lack of prognostic markers, tumor-escape mechanisms and 
frequent relapse upon surgical intervention, treatment of hepatocellular carcinoma 
(HCC) remains challenging. In this issue of Clinical Cancer Research, Groß and 
colleagues characterize a rodent model, which might help identify novel drugs for 
combinatorial sorafenib-based therapies for HCC. 
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In this issue of Clinical Cancer Research, Groß and colleagues (1) performed 
multiparametric multimodal imaging (MRI) and PET, and applied array CGH 
analyses to determine genetic heterogeneity and identify differences between 
commonly used rat hepatocellular carcinoma (HCC) model systems. HCC is the 
second most common cause of cancer-related death in humans worldwide and 
constitutes a major health problem in developing and industrialized countries. It 
comprises a clinically and pathologically heterogeneous spectrum of tumors with 
variable molecular and histological changes. In general, HCC prognosis is still poor, 
despite massive efforts by experimental and clinical HCC researchers in the past 
years, and less than 40% of patients are currently eligible for curative treatments 
(e.g., liver resection or transplantation). Thus, identification and development of 
appropriate treatments for particular HCC subtypes is imperative. Characterization of 
existing and generation of novel pre-clinical HCC rodent models recapitulating 
human disease and treatment response should help in selecting novel drugs for 
clinical trials. 
Challenges for progress in HCC treatment are manifold, including the lack of 
clinically relevant and applicable molecular classifications of HCC for treatment 
stratification and the availability of suitable pre-clinical animal models that 
recapitulate pathology and characteristics of human HCC subtypes, as well as 
treatment responsiveness. Several attempts to classify HCC based on genetic, 
transcriptional, methylation or miRNA levels have been made: Whole-exome 
sequence analysis of 250 HCC identified the most prevalent mutations (TERT 
promoter, CTNNB1, TP53, ARID1A and AXIN1) and signatures associated with HBV 
infection, alcohol intake, tobacco and other genotoxic substances (2). HCC gene 
expression studies identified tumor subgroups G1-G6, each associated with 
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particular clinical and genetic parameters, including chromosome stability, with G1-
G3 tumors being unstable and G4-G6 tumors being more stable (3). A recent meta-
analysis of 603 HCC patients demonstrated that common transcriptome-based 
subclasses exist across multiple studies, supporting the idea that there is a 
commonality in the global molecular status of HCC, irrespective of the heterogeneity 
in worldwide populations (4). The subclasses of aggressive tumors (termed S1 and 
S2) associated with a larger tumor size and poor histological differentiation 
corresponded to the “proliferation class” with poor survival. The “proliferation class” 
was characterized by activation of the Notch signaling pathway, while mutations in 
the CTNNB1 gene were enriched in the “non-proliferation class” (S3). This provided 
the basis for studying the molecular background of each HCC class. However, these 
and other classification proposals have largely failed to be integrated into clinical 
practice for the management of HCC patients - the ultimate goal of a clinically useful 
classification. 
In 2008, significant progress was achieved when increased survival of patients 
with advanced HCC was reported following treatment with sorafenib (Nexavar®) in a 
phase III trial (5). Based on these studies, stratification of patients that benefit from 
sorafenib treatment (6) was initiated, and a mechanism of sorafenib resistance in 
liver cancer (7) was identified. It is expected that improved patient stratification, as 
well as combinatorial treatments, might enhance the efficacy of sorafenib. Another 
challenge for the development of HCC treatment is the substantial degree of tumor 
heterogeneity, present not only within the tissue, but also on an intra-tumoral level 
(8). 
Another limitation is the lack of suitable pre-clinical rodent models in which to 
test mono- or combinatorial treatments. Ideally, pre-clinical models should faithfully 
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reflect the complexity and heterogeneity of human pathology. Several rodent HCC 
models recapitulate features of chronic liver disease caused by chronic inflammation, 
genotoxic (9) or metabolic stress (10, 11). However, it has become apparent that 
most rodent models reflect in most cases “only” particular features found in certain 
subtype(s) of human HCC - and that treatment success in these models does not 
necessarily correlate with successful translation to the clinics. Thus, existing as well 
as future rodent models have to be stratified more thoroughly on histological, genetic 
and molecular levels, as well as for their responsiveness to different treatments. 
Moreover, these parameters have to be correlated with human HCC in order to 
identify which human HCC subtype they most closely resemble, and for which 
treatments they could be used as a pre-clinical model. 
In the current study, Groß and colleagues induce HCC in rats using two 
different methods: one induced by di-ethyl-nitrosamine (DEN), and the other induced 
by orthotopically implanted (McA) rat HCC (Fig. 1). Based on histology, genetic 
analyses and multimodal imaging, they found liver damage only in DEN-treated rats. 
Moreover, DEN-induced liver tumors displayed G1-3 grading compared to the 
uniform G3 grading found in McA tumors. Moreover, DEN tumors exhibited lower 
mean growth rates and FDG uptake and higher diffusion and perfusion values 
compared to McA tumors. Finally, DEN-induced tumors were responsive to sorafenib 
treatment, whereas orthotopically implanted (McA) rat HCC were not. These findings 
indicate important differences in treatment responses between model systems, and 
thus might be of translational relevance. Further, based on the outcome of sorafenib 
monotherapy, the data suggest that the rat DEN model might be suitable for future 
testing of novel combinatorial therapy including sorafenib. They further underline that 
thorough analysis and comparison to human pathology has to be performed in order 
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get a realistic assessment of the applicability of each rodent models. Moreover, the 
outcome of ongoing and completed clinical trials with human HCC patients using 
sorafenib combination therapy should be compared to the DEN rat model. Similar 
responses in the DEN rat model and human trials would further validate the human 
relevance of this model. Moreover, the mouse DEN model should also be 
investigated, given its amenability to gene manipulation and responsiveness to 
sorafenib (12). 
Still, the study by Groß and colleagues leaves some open questions: (1) DEN 
is a chemical carcinogen and thus reflects only particular HCC etiologies (e.g., toxin-
induced). DEN treatment hardly recapitulates a chronic liver disease state 
characterized by persistent liver damage, compensatory proliferation and 
subsequent chromosomal aberrations, the background on which the majority of HCC 
arise. (2) Interestingly, although amplification of VEGF or VEGFR is reported to be a 
stratification criterion for a more efficient therapy in human patients (e.g., long-term 
survival), it is the orthotopically implanted (McA) rat HCC (sorafenib non-responders) 
which predominantly display amplification of VEGF or VEGFR. (3) Although partial 
treatment responses were reported for sorafenib in the DEN model, it has not been 
identified which (a) molecular changes (e.g., BRAF point mutations having been 
reported in a subpopulation of DEN-induced murine liver tumors), or (b) which 
histological features were related to sorafenib responsiveness. (4) As stated by the 
authors, different rat strains and sorafenib treatment regimens were used in this 
study for DEN and McA. Thus, the question remains whether longer sorafenib 
treatment or earlier treatment start might have also induced a response in the McA 
model. 
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In summary, this study underlines that stratification and comparison of rodent 
models with human HCC is important in order to validate their applicability, although 
this might be difficult in most cases and may never fit perfectly to a particular human 
subtype. Importantly, this study also shows that treatment response can be a critical 
stratification criterion, potentially providing a basis for future validation experiments 
(e.g., combinatorial treatment) - that ultimately might be more clinically relevant. 
Thus, the study by Groß and colleagues is an important first step in establishing and 
identifying useful pre-clinical rodent models for HCC research. 
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Figure 1. Differences of di-ethyl-nitrosamine treated and the McA HCC rat models 
and their possible usefulness for further studies on sorafenib-based combinatorial 
treatment. Groß and colleagues (1) show that DEN-treated rats are sorafenib-
responsive and fulfill the criteria to be used for future pre-clincial trial testing of 
several drugs in a sorafenib-based combinatorial therapy. 
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